Natures Aid Ltd — Credit Assessment

Company: Natures Aid Ltd (02793629) | Sector: VMS manufacturing (SIC 10890) | Status: Active, 32 years trading

1. Credit Opinion: APPROVE

Natures Aid presents as a low-risk credit on both standalone and group fundamentals:

• Return to profit with momentum: FY2023 profit after tax of £922k versus a £488k loss in FY2022 — a £1.4m swing driven by 19.3% revenue growth (£12.8m → £15.3m) and a 6% reduction in administrative costs. That combination of top-line growth and cost discipline is exactly what we look for.
• Near-debt-free balance sheet: Total borrowings are just £55k of finance leases against £14.3m of shareholders' funds. Gearing is effectively nil (~0.4%).
• Strong parent: 75%+ owned by Stada UK Holdings Ltd, part of the STADA international pharmaceutical group. This provides implicit financial backing, group governance, and strategic stability — a material risk mitigant, though no formal guarantee is evidenced in the data.
• Longevity and defensive sector: 32 years trading in consumer healthcare/VMS, a category with resilient demand through economic cycles. GMP-standard manufacturing and diversified channels (independents, wholesalers, grocers, export, private label) reduce concentration risk.
• Clean compliance record: No overdue filings, no insolvency markers, no director disqualifications.

The FY2022 loss demonstrates earnings are not immune to cost pressures, and the accounts are unaudited, but neither detracts materially from the overall picture.

2. Financial Strength

• Equity-funded balance sheet: Net assets of £14.3m represent 85% of total assets — an exceptionally strong capital base for a company of this size.
• Real asset backing: £4.8m of tangible fixed assets, including freehold land and buildings (£3.6m NBV), offering genuine security value and operational stability. A further £2.1m of goodwill sits on the balance sheet (14% of net assets) — acceptable, but worth noting it is not realisable security.
• Continued investment: £614k of tangible capex in FY2023 signals ongoing commitment to manufacturing capacity.
• Margin structure: Gross margin of 39% is healthy for the sector; operating margin of 6.1% and EBITDA of ~£1.27m (8.3% margin) provide adequate, though not generous, headroom.

3. Cash Flow Assessment

• Liquidity is strong: Current ratio of 4.7x and quick ratio of 3.2x. Net current assets of £7.9m comfortably cover any foreseeable short-term obligations. Interest payable of £2.5k is negligible — debt service is not a constraint.
• Working capital dynamics were the story of FY2023: A £1.5m inventory reduction (stock days fell from ~212 to ~123) released significant cash, but this was largely absorbed by a £1.8m rise in debtors. Trade debtor days deteriorated from ~98 to ~119 — receivables growing well ahead of the 19% sales increase. Cash still rose modestly (+£182k to £1.13m).
• Absolute cash is modest: £1.13m against a ~£14.4m annual cost base is roughly one month of operating costs. This is mitigated by highly liquid working capital, minimal fixed obligations, and group treasury access via STADA — but it means the company is not cash-rich in its own right.
• Creditor position is orderly: Trade creditor days stable at ~44; no signs of stretching suppliers to fund operations.

4. Monitoring Points

1. Receivables trend: Debtor days up ~21 days year-on-year. Watch for further deterioration, customer concentration in the grocery/wholesale channel, or any related-party balances within the STADA group.
2. Data currency: Detailed financials here end at FY2023. Accounts to December 2025 have since been made up — obtain FY2024/FY2025 figures to confirm the profit recovery has been sustained before finalising any material facility.
3. Unaudited accounts: The company files on an audit-exempt basis, so there is no independent assurance over the numbers. For significant exposures, request management accounts or group-reported figures.
4. Board stability: Recent director changes, including a resignation in November 2025, reflect ongoing adjustment under STADA ownership. Monitor for further churn at senior level.
5. Parent relationship: Support is implicit, not contractual. For larger facilities, consider requesting a parent guarantee or letter of comfort from Stada UK Holdings, and clarify any intercompany trading or treasury arrangements.
6. Earnings volatility: The FY2022 loss shows margins can compress quickly. Track gross margin and admin cost discipline in subsequent filings.